曲妥珠单抗 deruxtecan (T-DXd) 是一种抗体药物偶联物 (ADC)，针对多种肿瘤类型的 HER2 阳性恶性肿瘤。通过其独特的成分，T-DXd 实现了选择性有效负载递送，诱导细胞死亡并阻止肿瘤进展。临床试验最初调查了 T-DXd 对 HER2 阳性晚期或转移性乳腺癌、胃癌、肺癌和结直肠癌的疗效；然而，DESTINY-PanTumor02 试验的最新结果进一步强调了 T-DXd 的多功能性，促使美国 FDA 批准 T-DXd 用于治疗 HER2 阳性（免疫组织化学 [IHC] 3 ）实体瘤。此外，除了 T-DXd 对脑转移的功效外，T-DXd 在 HER2 低和 HER2 超低转移性乳腺癌中也显示出有希望的结果，这表明更广泛的患者群体可能受益。© 2024。作者（ s)，获得 Springer Nature Switzerland AG 的独家许可。

Trastuzumab deruxtecan (T-DXd) is an antibody-drug conjugate (ADC) targeting HER2-positive malignancies across various tumor types. Through its unique composition, T-DXd achieves selective payload delivery, inducing cell death and halting tumor progression. Clinical trials initially investigated T-DXd's efficacy in HER2-positive advanced or metastatic breast, gastric, lung, and colorectal cancers; however, recent results from the DESTINY-PanTumor02 trial further underscore T-DXd's versatility, prompting T-DXd's US FDA approval for HER2-positive (immunohistochemistry [IHC] 3+) solid tumors. Moreover, in addition to T-DXd's efficacy against brain metastasis, T-DXd is showing promising results in HER2-low and HER2-ultra-low metastatic breast cancer, indicating a broader population of patients who may benefit.© 2024. The Author(s), under exclusive licence to Springer Nature Switzerland AG.